- Home
- MLSS vs ACRV Comparison
MLSS vs ACRV Comparison
Compare MLSS & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLSS
- ACRV
- Stock Information
- Founded
- MLSS 1989
- ACRV 2018
- Country
- MLSS United States
- ACRV United States
- Employees
- MLSS N/A
- ACRV N/A
- Industry
- MLSS Industrial Specialties
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- MLSS Health Care
- ACRV Health Care
- Exchange
- MLSS Nasdaq
- ACRV Nasdaq
- Market Cap
- MLSS 42.4M
- ACRV 47.8M
- IPO Year
- MLSS 1995
- ACRV 2022
- Fundamental
- Price
- MLSS $0.40
- ACRV $1.99
- Analyst Decision
- MLSS Buy
- ACRV Buy
- Analyst Count
- MLSS 1
- ACRV 6
- Target Price
- MLSS $1.25
- ACRV $17.75
- AVG Volume (30 Days)
- MLSS 205.2K
- ACRV 1.1M
- Earning Date
- MLSS 11-14-2025
- ACRV 11-07-2025
- Dividend Yield
- MLSS N/A
- ACRV N/A
- EPS Growth
- MLSS N/A
- ACRV N/A
- EPS
- MLSS N/A
- ACRV N/A
- Revenue
- MLSS $9,083,205.00
- ACRV N/A
- Revenue This Year
- MLSS $16.06
- ACRV N/A
- Revenue Next Year
- MLSS $14.73
- ACRV $805.34
- P/E Ratio
- MLSS N/A
- ACRV N/A
- Revenue Growth
- MLSS 7.84
- ACRV N/A
- 52 Week Low
- MLSS $0.35
- ACRV $1.05
- 52 Week High
- MLSS $1.39
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- MLSS 41.02
- ACRV 52.67
- Support Level
- MLSS $0.35
- ACRV $1.91
- Resistance Level
- MLSS $0.44
- ACRV $2.46
- Average True Range (ATR)
- MLSS 0.04
- ACRV 0.16
- MACD
- MLSS -0.00
- ACRV -0.01
- Stochastic Oscillator
- MLSS 38.15
- ACRV 26.49
About MLSS Milestone Scientific Inc.
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.